Comparing Worldwide, National, and Independent Notifications about Adverse Drug Reactions Due to COVID-19 Vaccines
The rapid development of effective vaccines against COVID-19 is an extraordinary achievement. However, no medical product can ever be considered risk-free. Several countries have a pharmacovigilance system that detects, assesses, understands, and prevents possible adverse effects of a drug. To benef...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Information |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2078-2489/13/7/329 |
| _version_ | 1797406031635021824 |
|---|---|
| author | Francesco Branda Davide Tosi |
| author_facet | Francesco Branda Davide Tosi |
| author_sort | Francesco Branda |
| collection | DOAJ |
| description | The rapid development of effective vaccines against COVID-19 is an extraordinary achievement. However, no medical product can ever be considered risk-free. Several countries have a pharmacovigilance system that detects, assesses, understands, and prevents possible adverse effects of a drug. To benefit from such huge data sources, specialists and researchers need advanced big data analysis tools able to extract value and find valuable insights. This paper defines a general framework for a pharmaceutical data analysis application that provides a predefined (but extensible) set of functions for each data processing step (i.e., data collection, filtering, enriching, analysis, and visualization). As a case study, we present here an analysis of the potential side effects observed following the administration of the COVID-19 vaccines. The experimental evaluation shows that: (i) most adverse events can be classified as non-serious and concern muscle/joint pain, chills and nausea, headache, and fatigue; (ii) the notification rate is higher in the age group 20–39 years and decreases in older age groups and in very young people. |
| first_indexed | 2024-03-09T03:20:18Z |
| format | Article |
| id | doaj.art-5cad561029e74efb9e367cf32bf6f948 |
| institution | Directory Open Access Journal |
| issn | 2078-2489 |
| language | English |
| last_indexed | 2024-03-09T03:20:18Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Information |
| spelling | doaj.art-5cad561029e74efb9e367cf32bf6f9482023-12-03T15:11:12ZengMDPI AGInformation2078-24892022-07-0113732910.3390/info13070329Comparing Worldwide, National, and Independent Notifications about Adverse Drug Reactions Due to COVID-19 VaccinesFrancesco Branda0Davide Tosi1Department of Computer Science, Modeling, Electronics and Systems Engineering (DIMES), University of Calabria, 87036 Rende, ItalyDepartment of Theoretical and Applied Sciences (DiSTA), University of Insubria, 21100 Varese, ItalyThe rapid development of effective vaccines against COVID-19 is an extraordinary achievement. However, no medical product can ever be considered risk-free. Several countries have a pharmacovigilance system that detects, assesses, understands, and prevents possible adverse effects of a drug. To benefit from such huge data sources, specialists and researchers need advanced big data analysis tools able to extract value and find valuable insights. This paper defines a general framework for a pharmaceutical data analysis application that provides a predefined (but extensible) set of functions for each data processing step (i.e., data collection, filtering, enriching, analysis, and visualization). As a case study, we present here an analysis of the potential side effects observed following the administration of the COVID-19 vaccines. The experimental evaluation shows that: (i) most adverse events can be classified as non-serious and concern muscle/joint pain, chills and nausea, headache, and fatigue; (ii) the notification rate is higher in the age group 20–39 years and decreases in older age groups and in very young people.https://www.mdpi.com/2078-2489/13/7/329pharmacovigilancebig data analysisvaccine adverse eventvaccine safetyCOVID-19SARS-CoV-2 |
| spellingShingle | Francesco Branda Davide Tosi Comparing Worldwide, National, and Independent Notifications about Adverse Drug Reactions Due to COVID-19 Vaccines Information pharmacovigilance big data analysis vaccine adverse event vaccine safety COVID-19 SARS-CoV-2 |
| title | Comparing Worldwide, National, and Independent Notifications about Adverse Drug Reactions Due to COVID-19 Vaccines |
| title_full | Comparing Worldwide, National, and Independent Notifications about Adverse Drug Reactions Due to COVID-19 Vaccines |
| title_fullStr | Comparing Worldwide, National, and Independent Notifications about Adverse Drug Reactions Due to COVID-19 Vaccines |
| title_full_unstemmed | Comparing Worldwide, National, and Independent Notifications about Adverse Drug Reactions Due to COVID-19 Vaccines |
| title_short | Comparing Worldwide, National, and Independent Notifications about Adverse Drug Reactions Due to COVID-19 Vaccines |
| title_sort | comparing worldwide national and independent notifications about adverse drug reactions due to covid 19 vaccines |
| topic | pharmacovigilance big data analysis vaccine adverse event vaccine safety COVID-19 SARS-CoV-2 |
| url | https://www.mdpi.com/2078-2489/13/7/329 |
| work_keys_str_mv | AT francescobranda comparingworldwidenationalandindependentnotificationsaboutadversedrugreactionsduetocovid19vaccines AT davidetosi comparingworldwidenationalandindependentnotificationsaboutadversedrugreactionsduetocovid19vaccines |